# Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

> **NCT01508364** · — · COMPLETED · sponsor: **Bayer** · enrollment: 20 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY 43-9006)

## Key facts

- **NCT ID:** NCT01508364
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01508364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01508364, "Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01508364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*